Announcement • Jul 20
Armata Pharmaceuticals, Inc. Appoints David House as Chief Financial Officer, Effective July 17, 2026 Armata Pharmaceuticals, Inc. promoted and appointed David House as the Company's Chief Financial Officer, effective July 17, 2026. Mr. House previously served as the Company's Senior Vice President, Finance and principal financial officer since August 2024. Announcement • Jul 13
Armata Pharmaceuticals Receives Agreement From FDA On Initial Pediatric Study Plan For AP-SA02 For The Treatment Of Complicated Staphylococcus Aureus Bacteremia Armata Pharmaceuticals, Inc. has received agreement from the U.S. Food and Drug Administration on an Agreed Initial Pediatric Study Plan, which establishes the agreed regulatory framework for the future evaluation of AP-SA02 for the adjunct treatment of complicated Staphylococcus aureus bacteremia in pediatric patients. Agreement with the FDA on an iPSP is a regulatory requirement that must be met prior to submitting a Biologics License Application. The Agreed iPSP outlines a proposed pediatric development program targeting patients up to 17 years of age with complicated Staphylococcus aureus bacteremia, the same indication that Armata is pursuing in adults. Consistent with FDA requirements under the Pediatric Research Equity Act and with established FDA and European Medicines Agency regulatory frameworks, the FDA agreed that because the disease pathophysiology and treatment response in Staphylococcus aureus bacteremia are consistent across all age groups, pediatric studies should be deferred until safety and efficacy data are generated in adults in the planned Phase 3 program. Following completion of the adult Phase 3 study which is expected to initiate in the second half of 2026, the proposed program will comprise a single, multicenter, open-label, pediatric study to assess safety, tolerability, and clinical response outcomes. This strategy establishes a pathway for potential future expansion of AP-SA02 into the pediatric population while prioritizing patient safety and efficient clinical development. Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive Staphylococcus aureus or methicillin-resistant Staphylococcus aureus. AP-SA02 has received Qualified Infectious Disease Product and Fast Track designations from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy compared to best available antibiotic therapy alone (placebo) for the treatment of adults with complicated Staphylococcus aureus bacteremia. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025 in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated Staphylococcus aureus bacteremia, anticipated to initiate in the second half of 2026. Announcement • Jun 29
Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) dropped from Russell Microcap Value Benchmark Index Armata Pharmaceuticals, Inc.(NYSEAM:ARMP) dropped from Russell Microcap Value Benchmark Index 
